Next Article in Journal
DHX30 Coordinates Cytoplasmic Translation and Mitochondrial Function Contributing to Cancer Cell Survival
Next Article in Special Issue
Leukoplakia in the Oral Cavity and Oral Microbiota: A Comprehensive Review
Previous Article in Journal
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
Previous Article in Special Issue
RARβ Expression in Keratinocytes from Potentially Malignant Oral Lesions: The Functional Consequences of Re-Expression by De-Methylating Agents
 
 
Commentary
Peer-Review Record

The 4P: Preventing Preneoplasia through Patients Partnership

Cancers 2021, 13(17), 4408; https://doi.org/10.3390/cancers13174408
by Angélique Virgone 1,2,* and Sara Badreh 3
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2021, 13(17), 4408; https://doi.org/10.3390/cancers13174408
Submission received: 29 July 2021 / Revised: 26 August 2021 / Accepted: 29 August 2021 / Published: 31 August 2021
(This article belongs to the Special Issue Personalized Preventive Medicine of Oral Cancer)

Round 1

Reviewer 1 Report

The authors present a manuscript in which they deal with a very current and interesting topic, how can patient advocacy groups (PAGs) bring more awareness to preneoplasia preceding oral cancers and help patients after identifying a suspicious oral leukoplakia.

This reviewer believes that the authors should provide more data on initiatives similar to the one proposed, reporting the situation in France and other European countries.

This reviewer believes that the manuscript lacks data to support the thesis presented.

Furthermore, this reviewer believes that the work is more like a letter than a review in its current form.

In conclusion, this reviewer suggests to the authors either review their target by proposing to the journal the work in another form or enrich it with a detailed analysis of the available data that can support their thesis.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

In the manuscript " The 4P: Preventing Preneoplasia through Patients Partnership”, the authors aim to discuss the approach using patient advocacy groups to effectively prevent malignant transformation of oral potentially malignant disorders (OPMD).

There are some comments listed below:

  1. In Introduction, Page2 line 54, “Therefore, the main challenges for the prevention of leukoplakia transformation into cancer are to identify high-risk patients and treat them by chemotherapy in order to prevent OPMD transformation of the entire oral mucosa [5].”

-Since leukoplakia is only one of the OPMD, other lesions of OPMD can also transform to malignancy, even in higher transformation rate than leukoplakia, thus the “leukoplakia” here is better changed to OPMD.  

  1. In introduction, page 2-3 line 84-98, “2.1. World Health Organization (WHO) distinguishes 3 types of prevention [8]”: primary, secondary, tertiary…

-The arrangement of 2.2 secondary prevention… is better to be arranged as primary and tertiary.

  1. In introduction, page 3 line 112, “2.3. Primary Prevention: No smoking/No drinking campaigns”

   -Because subtitle for primary prevention has appeared in paragraph above, it is slightly confusing. Modify the subtitle will be better.

   -The contents in primary prevention (second and third paragraph) should be placed in secondary prevention.

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop